Copley Acquisition Corp announced a business combination agreement with Ignite Proteomics to advance precision oncology.

• On June 10, 2026, Copley Acquisition Corp entered into a Business Combination Agreement with Ignite Proteomics, LLC to advance precision oncology, subject to customary closing conditions and approvals [N1].

The company’s experienced management and broad network may facilitate sourcing and completing a business combination with a high-potential target in technology or lifestyle sectors. The announced agreement with Ignite Proteomics positions the company to enter the precision oncology market, potentially leveraging its capital and expertise to support growth. The flexibility in deal structuring and access to public markets could enhance value creation for shareholders post-combination.

The company faces risks inherent to SPACs, including the uncertainty of completing a business combination within the prescribed timeframe, potential shareholder redemptions reducing available capital, and competition from other acquisition vehicles. The management team’s limited time commitment and the absence of operating revenues until combination completion add to execution risk. The business combination with Ignite Proteomics is subject to customary closing conditions and approvals, with no assurance of consummation.

As a blank check company, Copley Acquisition Corp's competitive strengths lie in its experienced management team with deep networks in financial services and technology sectors, enabling access to quality acquisition targets. Its substantial trust account and public listing provide financial flexibility and an attractive platform for potential target companies seeking capital and public market access. However, the company’s success depends on identifying and consummating a suitable business combination, which carries inherent execution risks and competitive pressures from other acquisition entities.

• Execution Risk of Initial Business Combination: The company has not yet completed its initial business combination and faces risks related to identifying, negotiating, and closing a suitable transaction within the allowed timeframe.
• Dependence on Management and Network: Success depends on the management team’s ability to leverage their experience and network to source and complete a business combination, but their time commitment is not exclusive.
• Financial and Market Risks: Redemptions by public shareholders and competition from other acquisition entities may reduce available capital and complicate deal execution.
• Business Combination Specific Risks: The agreement with Ignite Proteomics is subject to closing conditions, shareholder approvals, and risks specific to Ignite’s business, with no guarantee of completion.

• Copley Acquisition Corp is a blank check company incorporated in the Cayman Islands on November 26, 2024, focused on effecting a business combination with one or more businesses.
• The company targets industries that complement its management team's background, focusing on technology and lifestyle sectors.
• It has not generated operating revenues to date and does not expect to until consummation of its initial business combination.
• Management and board have significant experience in financial services, financial technology, and investing in technology and lifestyle sectors, with a broad network for deal sourcing.
• The company intends to leverage its management's network and expertise to identify and acquire a target business, focusing on enabling technology and lifestyle services sectors.
• Potential targets may range from high-growth innovative companies to mature businesses with recurring revenues and strong cash flows.
• The company has a trust account with approximately $179 million as of March 19, 2026, to fund its initial business combination.
• It has flexibility to consummate the business combination using equity, debt, cash, or combinations thereof, but has not secured third-party financing yet.
• The company has entered into a Business Combination Agreement with Ignite Proteomics, LLC as of June 10, 2026, to advance precision oncology.
• The business combination is subject to risks including closing conditions, shareholder approvals, redemption levels, and risks specific to Ignite Proteomics.
• As of June 30, 2026, the company had cash and equivalents of $0, current assets of $121,224, current liabilities of $522,365, resulting in a current ratio of 0.23 and a cash ratio of 0.
• The company has no reported revenue but reported net income of $1,485,641 for the period ending June 30, 2026.
• The company is an emerging growth company and is subject to reporting obligations under the Exchange Act.
• The company has a completion window of up to 24 months from its IPO to complete its initial business combination, with provisions for extensions and liquidation if not completed.
• The company’s management team is not required to devote significant time exclusively to the company and may be involved with other businesses.
• The company’s business combination criteria include companies with disruptive technology or business models, defensible market positions, and potential to benefit from being publicly traded.
• The company’s initial business combination must meet the NYSE 80% fair market value test relative to the trust account balance.
• The company’s recent news includes the announcement of the business combination agreement with Ignite Proteomics on June 11, 2026.